Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bostwick says CNS teams miscast the brain as just another organ. He lists a blood-brain barrier built as an immune fortress, motor neurons whose axons stretch from spinal cord to ankle, and neurons that express roughly 10,000 genes with heavy alternative splicing and RNA transfer between cells.

Related Insights

Traditional models like rodents, non-human primates, iPSCs, and brain organoids fail to replicate complex human brain architecture, vasculature, and disease biology. Reperfusing intact donor human brains preserves native blood-brain barriers, endogenous CSF production, and human-specific targets to directly generate human pharmacology preclinically.

Historical failures in CNS drugs stem from treating severe, late-stage pathology. Success will come from using better biomarkers to intervene earlier and combining therapies. The speaker envisions a future of 'rational polypharmacy,' where drugs targeting different pathological drivers (e.g., excitability, inflammation) are used in concert.

Prior therapeutic strategies were flawed. Symptomatic treatments squeeze more function from the few remaining neurons until they also die. Disease-modifying drugs, like antibodies, are often ineffective because the blood-brain barrier allows less than 0.1% to reach the brain.

19 of 20 drugs fail because diseases like cancer and Alzheimer's require complex solutions, not a simple "turn one screw" fix. Massively scaled human tissue testing allows for exploring the vast search space needed to find these multi-target cures, which traditional methods cannot handle.

The catastrophic failure rate in drug development isn't just bad luck; it's a structural problem. It originates from the very first decision: researchers, biased by existing literature and simplistic models, fixate on a single biochemical target, ignoring the body's complex, multi-faceted nature.

Despite AI's power, 90% of drugs fail in clinical trials. John Jumper argues the bottleneck isn't finding molecules that target proteins, but our fundamental lack of understanding of disease causality, like with Alzheimer's, which is a biology problem, not a technology one.

The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.

New single-cell atlases of Parkinson's brains show that biological pathways are activated differently depending on the brain region and disease stage. This adds a critical layer of complexity, implying that a "disease-modifying" drug may need to be targeted to specific cell types at specific times, complicating clinical development.

The CNS biotech ecosystem has incredible momentum from new tools like advanced imaging, genetics, and AI. However, progress is stalled because the industry still uses outdated development frameworks, such as decades-old clinical trial designs and over-reliance on flawed animal models that fail to recapitulate human disease.

CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.

CNS drug failure stems from brain complexity, not targets | RiffOn